Medtronic plc broadened the approved use of its Affera mapping and ablation system with the Sphere-9 catheter, securing CE mark approval to treat ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes.The approval for the expanded use of the technology, beyond atrial fibrillation, opens up a sizeable new market. It is also a boon for the company, which is seeing its share of the electrophysiology market grow steadily.